Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects

Metabolic syndrome (MetS), a cluster of cardiometabolic risk factors, is a challenging public health issue. The aim of current study was to test the hypothesis that concentrations of plasma adropin and leptin differ between patients with MetS and comparable age- and sex-matched control groups. This...

Full description

Saved in:
Bibliographic Details
Published in:American journal of men's health 2017-03, Vol.11 (2), p.426-434
Main Authors: Yosaee, Somaye, Khodadost, Mahmoud, Esteghamati, Alireza, Speakman, John R., Shidfar, Farzad, Nazari, Mahdiyeh Nasab, Bitarafan, Vida, Djafarian, Kurosh
Format: Article
Language:English
Subjects:
Adiponectin
Adult
Anthropometry
Biomarkers - blood
Blood Proteins
Body Mass Index
Case-Control Studies
Health care
Humans
Leptin - blood
Male
Metabolic syndrome
Metabolic Syndrome - blood
Middle Aged
Obesity - blood
Peptides - blood
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metabolic syndrome (MetS), a cluster of cardiometabolic risk factors, is a challenging public health issue. The aim of current study was to test the hypothesis that concentrations of plasma adropin and leptin differ between patients with MetS and comparable age- and sex-matched control groups. This case-control study involved 153 subjects (51 per group). The study group included obese subjects with MetS and the two control groups included weight-matched subjects without MetS (“healthy”: obese) and normal weight subjects without MetS. Body composition parameters were measured using bioelectrical impedance analysis. Plasma levels of adropin, leptin, and their ratio were measured. Leptin was significantly different between obese patients with/without MetS groups and normal weight subjects. Patients with MetS had higher levels of leptin (14 ± 12.4) compared with those without MetS (11.2 ± 9.3 vs. 7 ± 7.1 obese and normal weight without MetS, respectively; p = .002). Compared with healthy obese and normal weight subjects, MetS subjects had lower levels of plasma adropin (p < .001) and a lower plasma adropin to leptin ratio (p < .001), which remained significant when adjusted for body fat mass by analysis of covariance (p < .001). This study demonstrates low levels of adropin are correlated with MetS and hence identify it as a potentially protective agent against MetS development. Variation in adropin levels may partly explain the “healthy obese” phenomenon.
ISSN:1557-9883
1557-9891
DOI:10.1177/1557988316664074